Jim Cramer Isn't Sure If There’s Upside In This Health Care Stock
Cramer favors Howmet, remains cautious on AeroVironment, Rocket, AtaiBeckley and MP Materials, citing competition and limited upside.
Stocks · News reference
AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026
As previously disclosed, AtaiBeckley Inc. (the "Company") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the "Merger Agreement"), with Eli Lilly and Company, an Indiana
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — AtaiBeckley Inc. (ATAI)
Filed: 2026-08-31 AccNo: 0001140361-26-035091 Size: 167 KB Item 8.01: Other Events
President Trump Say In A Social Media Post That The University Of Miami Shared Its 1994 Ibogaine Investigational New Drug Application With The Government, Which Will Help Accelerate Development As A Medical Treatment In The U.S.
Deal Dispatch: Nvidia Buys Hugging Face for $12.9 Billion, Barilla Acquires Goodles, Park Place Partners Bankruptcy
Major M&A deals include Flex buys EPC Power for $4.4 Billion, KKR acquires A1 Garage Door, Starman Optical Buys GoPro.
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
Nxera Pharma announced it will receive an $8.6 million milestone payment from Centessa Pharmaceuticals (a subsidiary of Eli Lilly) following late-stage development progress on selective orexin receptor 2 (OX2R) agonist candidates. The payment will be recognized as revenue in Q3 2026. Nxera retains rights to future development, commercialization milestones, and royalties from the OX2R agonist programs.
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.